MADISON, Wis. - Accuray (NASDAQ:ARAY) Incorporated (NASDAQ: ARAY) has presented new data at the 2024 Radiosurgery Society Meeting in Chicago, indicating that the CyberKnife System could be a viable option for treating high-risk and recurrent prostate cancer. The data is derived from clinical studies and years of peer-reviewed scientific manuscripts, with recent findings highlighting the system's precision and potential to maintain quality of life post-treatment.
The CyberKnife System employs stereotactic body radiation therapy (SBRT), a technique that delivers concentrated doses of radiation over fewer sessions than traditional therapy. The system's sub-millimeter accuracy allows for the treatment of prostate cancer close to sensitive areas such as the bladder and rectum.
This precision is particularly important given the prostate gland's tendency to move unpredictably during treatment, a challenge that the system's real-time AI-driven motion tracking and synchronization technology, Synchrony®, addresses by adapting the radiation beam to the tumor's position in real-time.
According to the studies presented, the CyberKnife platform can effectively manage high-risk prostate cancer in 4-5 sessions, as opposed to the 30-40 sessions required by conventional radiation therapy. Three years post-treatment, patients showed favorable biochemical control and largely returned to near-baseline urinary and bowel function.
Accuray emphasizes its commitment to advancing radiation therapy and improving patient outcomes, as reflected in the continuous innovation of the CyberKnife System. The company, headquartered in Madison, Wisconsin, aims to meet a broad spectrum of patient needs through its radiation therapy solutions.
This article is based on a press release statement from Accuray Incorporated.
InvestingPro Insights
As Accuray Incorporated (NASDAQ: ARAY) champions the capabilities of its CyberKnife System for treating high-risk prostate cancer, the company's financial health and market performance provide a broader context for evaluating its potential. InvestingPro data indicates a market capitalization of $245.94 million, reflecting the size and scale of the company within the medical device industry. Despite the innovative strides in treatment technology, analysts have tempered expectations with revisions to earnings, suggesting that Accuray may not achieve profitability in the current year. This aligns with the company's negative P/E ratio of -16.49, as of the last twelve months ending Q2 2024, which underscores the financial challenges Accuray faces.
InvestingPro Tips also reveal that Accuray is trading near its 52-week low and does not pay a dividend to shareholders, which may influence investor sentiment and decision-making. The company's stock performance has seen a year-to-date price total return of -12.37%, reflecting recent market trends and investor responses to the company's financial position and outlook.
For those considering an investment in Accuray, or simply seeking to understand the company's financial landscape in relation to its technological advancements, additional InvestingPro Tips are available. With a total of 7 tips listed on InvestingPro, including insights on valuation multiples and profitability metrics, investors can gain a more nuanced understanding of the company's financial health. To explore these insights further, visit https://www.investing.com/pro/ARAY and remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.